A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Clinical trial NCT04182204 · COMPLETED
Trial details
- NCT number
- NCT04182204
- Sponsor
- Hoffmann-La Roche
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-02-07
- Primary completion
- 2024-11-29
- Enrollment
- 270
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.